Exhibition Recap | Collaboration & Symbiosis
Release Date:
2024-01-19 13:50
Exhibition Review
The COVID-19 pandemic has thrust mRNA vaccines into the global spotlight, disrupting the long-standing dominance of first-generation live attenuated and inactivated vaccines as well as second-generation subunit vaccines worldwide and paving the way for the iterative advancement of third-generation vaccines. mRNA vaccines offer numerous advantages, including rapid development, high safety, robust immune protection, and efficient manufacturing, thereby opening up new avenues for the prevention and control of infectious diseases. Moreover, mRNA holds tremendous potential for applications in immunotherapy, antibody and protein replacement therapies, cell therapy, regenerative medicine, gene editing, and gene therapy delivery systems.
On January 16–17, 2024, the xRNA Nucleic Acid Drug Development and Innovation Forum was officially held in Suzhou. The event brought together experts and scientists from domestic and international research institutions specializing in nucleic acid vaccines and therapeutics, who shared their insights on a wide range of topics—including next-generation mRNA/circRNA vaccines and drugs, oligonucleotide drug development, preclinical and clinical research, delivery technologies and process development, and strategies to accelerate industrialization and market penetration—thereby expressing great optimism and enthusiasm for the future of the industry.
The Vaccine and Infectious Disease Drug R&D Evaluation Technology Platform is a high-quality service platform jointly developed by Beike Pharmaceuticals and Hycells Biotechnology to serve our clients. Backed by a robust team of expert consultants and leveraging highly pathogenic bacterial and viral strains, the platform leverages technology R&D, scale-up and manufacturing, quality-system control, and market-oriented delivery channels to enable vaccine manufacturers, pharmaceutical companies, CROs, research institutes, and other organizations to fulfill their respective roles and maximize their capabilities. To date, the platform has accumulated numerous successful case studies, including in vitro neutralization assays and in vivo challenge studies for common pathogens such as SARS-CoV-2, varicella-zoster virus, influenza virus, respiratory syncytial virus, and Helicobacter pylori.
Introduction to the Vaccine and Infectious Disease Drug R&D Platform
-
The existing strains and toxins available for service effectively cover the mainstream R&D scope of vaccines and infectious disease therapeutics.
-
Provide ABSL-2/3 level Biosafety experimental environments, including in vitro and large- and small-animal challenge studies
-
Provide 100+ Services related to infectious disease testing, with quality control conducted in accordance with GLP standards and quality management documentation. 150+ portion (having established the company’s own technological barriers and standardized SOPs that align with industry development needs)
-
Providing compliant, standardized, and end-to-end professional CRO services for vaccine and infectious disease drug R&D.
Advantages of the Vaccine and Infectious Disease Drug R&D Platform
-
Abundant microbial and toxin strain resources
Covers the mainstream R&D scope in the market.
Possessing an extensive strain library resource
-
Secure, compliant, and traceable
Compliant Use of a BSL-3 Biosafety Laboratory
CFDA/FDA on-site inspection is acceptable.
Quality control is conducted in accordance with GLP standards and meets the requirements for IND submission.
-
Professional Project Team
The team possesses in-house R&D capabilities for vaccines, drugs, and diagnostic reagents.
The expert team simultaneously covers key areas such as biosafety and quality control.
-
Related Project Cases
Passed on-site audits and was shortlisted as a supplier for several leading enterprises.
Extensive experience in IND submissions and on-site inspections
-
Standardized and End-to-End Service Capabilities
Strong in-house R&D and standardization capabilities
Vaccine developers understand market demand.
A prospective, standardized, end-to-end evaluation system can be established.
On-site Exchange Photos of Hycells Biotechnology and Beike Pharmaceuticals with Clients
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board